These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. Barrio M; Fendler WP; Czernin J; Herrmann K Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869 [TBL] [Abstract][Full Text] [Related]
24. Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives. Lin M; Ta RT; Kairemo K; Le DB; Ravizzini GC Cancer Biother Radiopharm; 2021 Apr; 36(3):237-251. PubMed ID: 32589458 [TBL] [Abstract][Full Text] [Related]
25. Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands. Naik M; Khan SR; Lewington V; Challapalli A; Eccles A; Barwick TD Br J Radiol; 2024 Aug; 97(1160):1391-1404. PubMed ID: 38733571 [TBL] [Abstract][Full Text] [Related]
26. Prostate-Specific Membrane Antigen Biology and Pathophysiology in Prostate Carcinoma, an Update: Potential Implications for Targeted Imaging and Therapy. Maes J; Gesquière S; De Spiegeleer A; Maes A; Van de Wiele C Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273701 [TBL] [Abstract][Full Text] [Related]
27. Preclinical Evaluation of Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722 [TBL] [Abstract][Full Text] [Related]
28. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging. Hofman MS; Iravani A PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455 [TBL] [Abstract][Full Text] [Related]
29. Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA). Ray Banerjee S; Pullambhatla M; Foss CA; Falk A; Byun Y; Nimmagadda S; Mease RC; Pomper MG J Med Chem; 2013 Aug; 56(15):6108-21. PubMed ID: 23799782 [TBL] [Abstract][Full Text] [Related]
30. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy. Arsenault F; Beauregard JM; Pouliot F Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893 [TBL] [Abstract][Full Text] [Related]
31. Tc-99m-PSMA imaging allows successful radioguided surgery in recurrent prostate cancer. Kratzik C; Dorudi S; Schatzl M; Sinzinger H Hell J Nucl Med; 2018; 21(3):202-204. PubMed ID: 30411731 [TBL] [Abstract][Full Text] [Related]
32. Intraindividual Comparison of Rathke H; Afshar-Oromieh A; Giesel FL; Kremer C; Flechsig P; Haufe S; Mier W; Holland-Letz T; De Bucourt M; Armor T; Babich JW; Haberkorn U; Kratochwil C J Nucl Med; 2018 Sep; 59(9):1373-1379. PubMed ID: 29371410 [TBL] [Abstract][Full Text] [Related]
34. [¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Kratochwil C; Giesel FL; Eder M; Afshar-Oromieh A; Benešová M; Mier W; Kopka K; Haberkorn U Eur J Nucl Med Mol Imaging; 2015 May; 42(6):987-8. PubMed ID: 25573634 [No Abstract] [Full Text] [Related]
35. Enhancing Treatment Efficacy of Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544 [TBL] [Abstract][Full Text] [Related]
36. PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future? Sallam M; Nguyen NT; Sainsbury F; Kimizuka N; Muyldermans S; Benešová-Schäfer M Theranostics; 2024; 14(8):3043-3079. PubMed ID: 38855174 [TBL] [Abstract][Full Text] [Related]
37. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer. Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647 [TBL] [Abstract][Full Text] [Related]
38. Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. Eder M; Schäfer M; Bauder-Wüst U; Haberkorn U; Eisenhut M; Kopka K Prostate; 2014 May; 74(6):659-68. PubMed ID: 24464532 [TBL] [Abstract][Full Text] [Related]
39. (R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors. Gourni E; Canovas C; Goncalves V; Denat F; Meyer PT; Maecke HR PLoS One; 2015; 10(12):e0145755. PubMed ID: 26700033 [TBL] [Abstract][Full Text] [Related]
40. [PSMA-based theranostics for prostate cancer : From imaging to treatment]. Ilhan H; la Fougère C; Krause BJ Urologe A; 2020 May; 59(5):617-625. PubMed ID: 32377764 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]